Characteristics of Participants Screened and Randomized to the Melanoma Self Surveillance Trial
JAMA Dermatology · 01.05.2026 · 162 (5) · 457
DOI: 10.1001/jamadermatol.2026.0083 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Dermatology, erschienen am 01.05.2026. Verfasst von Ellie Medcalf und 29 weiteren Autor:innen. Beteiligte Einrichtung: Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Self-Examination, Early Detection of Cancer. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance The MEL-SELF randomized clinical trial (RCT) evaluated patient-led surveillance as an alternative model of follow-up. The baseline characteristics of participants provide insights into current unmet clinical needs of this population.
Objective
To describe the baseline characteristics of people screened for and randomized to the MEL-SELF RCT, and those potentially eligible but not randomized. Design, Setting, and Participants Baseline data from the RCT’s recruitment processes, from December 2021 to June 2024, were analyzed. Data were collected from dermatologist- and general practitioner–led skin cancer clinics in Australia, and included adults previously treated for early-stage melanoma (by American Joint Committee on Cancer Staging Manual [ AJCC, 0-II]) attending routinely scheduled clinics, with a skin self-examination (SSE) partner, and a smartphone. Analysis took place between August 2025 and December 2025.
Interventions
Participants were invited to participate in the MEL-SELF trial with randomization (1:1) to patient-led surveillance (usual care plus reminders to perform SSE, mobile dermatoscope, teledermatologist assessment, fast-tracked unscheduled clinic visits) or clinician-led surveillance (usual care) for 12 months. Main Outcomes and Measures The main outcomes were enrollment; active run-in and allocation results, sociodemographic and clinical characteristics; SSE knowledge, attitudes, and practice (frequency and thoroughness); and psychological measures including fear of cancer recurrence (FCR) at baseline.
Results
Of 1226 patients screened and potentially eligible, 504 were randomized to patient-led (n = 251) or clinician-led (n = 253) surveillance. Overall, 295 were female individuals (59%) and 209 were male individuals (41%), most were aged 50 years and older (mean [SD] age, 56.0 [11.6] years) and had a highest substage of melanoma in situ (245 [49%]) or IA (217 [43%]). SSE practice varied substantially, ranging from no SSE in the previous 12 months (103 [20%]) to weekly or monthly SSE (160 [32%]). A high proportion (232 [46%]) reported clinically significant levels of FCR, which was associated with being female, younger age, and higher depression, anxiety, and stress scores. FCR was associated with a higher perceived lifetime risk of melanoma, but not with participants’ actual calculated risk of a subsequent new primary melanoma (OR, 1.00; 95% CI, 0.99-1.01). Characteristics were similar between the trial population and potentially eligible patients who completed the baseline questionnaire but were not randomized (n = 225).
Conclusions
This secondary analysis of baseline characteristics in the MEL-SELF trial indicates suboptimal SSE practice and clinically significant levels of FCR. Future reports will evaluate comparative effects of patient-led surveillance on health, psychological and health resource use outcomes. Trial Registration anzctr.org.au Identifier: ACTRN12621000176864
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.
- Heat and Health Research Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
- Biostatistics Centre, University of Otago, Dunedin, New Zealand.
- National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia.
- Centre for Health Services Research, The University of Queensland, Brisbane, Queensland, Australia.
- The Daffodil Centre, The University of Sydney, Sydney, New South Wales, Australia.
Zitieren
APA
Medcalf, E., Ackermann, D. M., Williams, J. T. W., Turner, R. M., Espinoza, D., Wu, Z., Fann, A., Kharel, P., Janda, M., Cust, A. E., Irwig, L., Hersch, J. K., Low, D., Low, C., Guitera, P., Martin, L. K., Soyer, H. P., Azzi, A., Lilleyman, A., …, & Bell, K. J. L. (2026). Characteristics of Participants Screened and Randomized to the Melanoma Self Surveillance Trial. JAMA Dermatology, 162(5), 457. https://doi.org/10.1001/jamadermatol.2026.0083
Vancouver
Medcalf E, Ackermann DM, Williams JTW, Turner RM, Espinoza D, Wu Z, et al. Characteristics of Participants Screened and Randomized to the Melanoma Self Surveillance Trial. JAMA Dermatology. 2026;162(5):457. doi:10.1001/jamadermatol.2026.0083
BibTeX
@article{Medcalf2026,
author = {Medcalf, Ellie and Ackermann, Deonna M and Williams, Jake T W and Turner, Robin M and Espinoza, David and Wu, Zhuohan and Fann, Adrian and Kharel, Priti and Janda, Monika and Cust, Anne E and Irwig, Les and Hersch, Jolyn K and Low, Donald and Low, Cynthia and Guitera, Pascale and Martin, Linda K and Soyer, H Peter and Azzi, Anthony and Lilleyman, Alister and Rosengren, Helena and Mar, Victoria and Mcrae, Michelle Y and Glanz, Amanda and Collgros, Helena and Emery, Jon D and Murchie, Peter and Morton, Rachael L and Ferguson, Peter and McLean, Catriona and Bell, Katy J L},
title = {Characteristics of Participants Screened and Randomized to the Melanoma Self Surveillance Trial},
journal = {JAMA Dermatology},
year = {2026},
volume = {162},
number = {5},
pages = {457},
doi = {10.1001/jamadermatol.2026.0083}
}
EUVIMED